Quantbot Technologies LP Invests $1.16 Million in Inspire Medical Systems, Inc. $INSP

Quantbot Technologies LP bought a new position in Inspire Medical Systems, Inc. (NYSE:INSP) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 25,954 shares of the company’s stock, valued at approximately $1,158,000. Quantbot Technologies LP owned approximately 0.09% of Inspire Medical Systems at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada grew its position in Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after buying an additional 4,528 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Inspire Medical Systems in the first quarter valued at $524,000. Goldman Sachs Group Inc. lifted its position in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after acquiring an additional 18,857 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after acquiring an additional 577 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in shares of Inspire Medical Systems during the 2nd quarter worth $931,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Bank of America cut Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a report on Friday, May 22nd. Truist Financial reiterated a “hold” rating and issued a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $60.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Piper Sandler boosted their price objective on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Evercore set a $54.00 price objective on Inspire Medical Systems in a report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $66.19.

Insider Transactions at Inspire Medical Systems

In related news, insider Jason P. Kelly sold 963 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $61.23 on Wednesday. The firm’s 50 day moving average price is $51.95 and its two-hundred day moving average price is $52.50. Inspire Medical Systems, Inc. has a twelve month low of $38.91 and a twelve month high of $147.03. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 13.25, a PEG ratio of 4.67 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company’s revenue for the quarter was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.